0001104659-23-126599.txt : 20231218 0001104659-23-126599.hdr.sgml : 20231218 20231218071029 ACCESSION NUMBER: 0001104659-23-126599 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231218 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231218 DATE AS OF CHANGE: 20231218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 231492228 BUSINESS ADDRESS: STREET 1: 400 ATLANTIC STREET, SUITE 500 CITY: STAMFORD STATE: CT ZIP: 06901 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 400 ATLANTIC STREET, SUITE 500 CITY: STAMFORD STATE: CT ZIP: 06901 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 8-K 1 tm2333104d1_8k.htm FORM 8-K
false 0001346830 0001346830 2023-12-18 2023-12-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) December 18, 2023

  

CARA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36279   75-3175693

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

         

4 Stamford Plaza

107 Elm Street, 9th Floor

Stamford, Connecticut

       06902
(Address of principal executive offices)       (Zip Code)
         
Registrant's telephone number, including area code (203) 406-3700

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

  

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, par value $0.001 per share CARA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨.

 

 

 

 

 

 Item 7.01. Regulation FD Disclosure.

 

On December 18, 2023, Cara Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing the outcome from the dose-finding Part A of the KIND 1 study evaluating the efficacy and safety of oral difelikefalin as adjunct therapy to topical corticosteroids (“TCS”) for moderate-to-severe pruritus in adult patients with atopic dermatitis (“AD”). Oral difelikefalin as adjunct to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone, resulting in the Company’s decision to discontinue its clinical program in pruritus associated with AD. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 7.01.

 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.

 

 Item 8.01. Other Information.

 

On December 18, 2023, the Company issued the Press Release announcing the outcome from the dose-finding Part A of the KIND 1 study evaluating the efficacy and safety of oral difelikefalin as adjunct therapy to TCS for moderate-to-severe pruritus in adult patients with AD. Oral difelikefalin as adjunct to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone, resulting in the Company’s decision to discontinue its clinical program in pruritus associated with AD.

 

The Phase 3, two-part, multicenter, randomized, double-blind, placebo-controlled, 12-week study was designed to investigate the use of oral difelikefalin as adjunctive treatment to topical corticosteroids in approximately 287 patients with AD. Patients were randomized to receive oral difelikefalin 0.25 mg tablets twice a day (“BID”) plus TCS, difelikefalin 0.5 mg tablets BID plus TCS, placebo tablets BID plus TCS or placebo tablets BID plus vehicle.

 

Primary Endpoint

 

The primary efficacy endpoint was the proportion of patients with a ≥4-point improvement at Week 12 from baseline in the worst itch numerical rating scale.

 

Oral difelikefalin as adjunct therapy to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone. Oral difelikefalin was generally well tolerated with a safety profile similar to prior trials.

 

Item 9.01. Financial Statements and Exhibits. 

 

(d) Exhibits

 

Exhibit No.  Description

 

99.1 Press Release dated December 18, 2023
104 Cover page interactive data file (formatted as Inline XBRL)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

CARA THERAPEUTICS, INC.  
   
By: /s/ RYAN MAYNARD  
  Ryan Maynard  
  Chief Financial Officer  
  (Principal Financial and Accounting Officer)  

 

Date: December 18, 2023

 

3

 

 EX-99.1 2 tm2333104d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

 

– Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruritus associated with atopic dermatitis –

 

– Late-stage oral difelikefalin clinical programs for pruritus associated with notalgia paresthetica and advanced chronic kidney disease continue to enroll on track with key data readouts expected in 2H24 –

 

– Cara expects to end 2023 with approximately $100 million in cash –

 

STAMFORD, Conn., December 18, 2023 – Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KIND 1 study evaluating the efficacy and safety of oral difelikefalin as adjunct therapy to topical corticosteroids (TCS) for moderate-to-severe pruritus in adult patients with atopic dermatitis (AD). Oral difelikefalin as adjunct to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone, resulting in the Company’s decision to discontinue its clinical program in pruritus associated with atopic dermatitis.

 

“We are disappointed with the outcome of this study recognizing that comparing the adjunctive use of oral difelikefalin with TCS to TCS alone represented a high clinical bar based on anticipated real-world commercial use. Importantly, we believe that there is no readthrough to our other late-stage clinical programs for oral difelikefalin as monotherapy without TCS in different indications and patient populations, namely notalgia paresthetica (NP) and advanced chronic kidney disease (CKD),” said Joana Goncalves, MD, Chief Medical Officer of Cara Therapeutics. “On behalf of the Cara team, I would like to thank the patients and investigators who participated in this trial and our team for their unwavering commitment to its execution.”

 

KIND 1 was a Phase 3, two-part, multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of oral difelikefalin as adjunct therapy to TCS for moderate-to-severe pruritus in adults with AD. In Part A, patients (n=287) were randomized to receive oral difelikefalin 0.25 mg tablets twice a day (BID) plus TCS, difelikefalin 0.5 mg tablets BID plus TCS, placebo tablets BID plus TCS or placebo tablets BID plus vehicle. The primary endpoint was the proportion of patients with a ≥4-point improvement at Week 12 from baseline in the worst itch NRS.

 

 

 

 

 

Oral difelikefalin as adjunct therapy to TCS did not demonstrate a meaningful clinical benefit compared to TCS alone. Oral difelikefalin was generally well tolerated with a safety profile similar to prior trials.

 

Cara expects to end 2023 with approximately $100 million in cash. This amount includes the $17.5 million already received from HealthCare Royalty, less certain expenses, and the first milestone payment of $20 million, which was triggered by the achievement of the milestone this month and is expected to be received by year-end 2023.

 

About Cara Therapeutics

 

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has a Phase 3 program ongoing for the treatment of moderate-to-severe pruritus in patients with advanced chronic kidney disease and a Phase 2/3 program for moderate-to-severe pruritus in patients with notalgia paresthetica. For more information, visit www.CaraTherapeutics.com and follow the company on X (Twitter), LinkedIn and Instagram.

 

Forward-looking Statements

 

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the Company’s plans to discontinue its clinical program in pruritus associated with atopic dermatitis, timing of enrollment and data readouts from the Company’s planned and ongoing clinical trials, and the Company’s cash balance at year end. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include the risks inherent in the launch of new products, including that our commercial partners may not perform as expected, risks inherent in the clinical and regulatory development of pharmaceutical products, and the risks described more fully in Cara Therapeutics’ filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ending December 31, 2022 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission, including its Form 10-Q for the quarter ended September 30, 2023. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

 

 

 

 

MEDIA CONTACT:

Annie Spinetta

6 Degrees

973-768-2170

aspinetta@6degreespr.com

 

INVESTOR CONTACT:

Iris Francesconi, Ph.D.

Cara Therapeutics

203-406-3700

investor@caratherapeutics.com

 

 

 EX-101.SCH 3 cara-20231218.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cara-20231218_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cara-20231218_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2333104d1_ex99-1img001.jpg GRAPHIC begin 644 tm2333104d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Dec. 18, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 18, 2023
Entity File Number 001-36279
Entity Registrant Name CARA THERAPEUTICS, INC.
Entity Central Index Key 0001346830
Entity Tax Identification Number 75-3175693
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4 Stamford Plaza
Entity Address, Address Line Two 107 Elm Street
Entity Address, Address Line Three 9th Floor
Entity Address, City or Town Stamford
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06902
City Area Code 203
Local Phone Number 406-3700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CARA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2333104d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001346830 2023-12-18 2023-12-18 iso4217:USD shares iso4217:USD shares false 0001346830 8-K 2023-12-18 CARA THERAPEUTICS, INC. DE 001-36279 75-3175693 4 Stamford Plaza 107 Elm Street 9th Floor Stamford CT 06902 203 406-3700 false false false false Common Stock, par value $0.001 per share CARA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" M / " 7X0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 M" !..9)7)!Z;HJT #X 0 &@ @ '>$0 >&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !..9)799!YDAD! #/ P M$P @ '#$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 .."0 ) #X" -% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://caratherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports cara-20231218.xsd cara-20231218_lab.xml cara-20231218_pre.xml tm2333104d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2333104d1_8k.htm": { "nsprefix": "CARA", "nsuri": "http://caratherapeutics.com/20231218", "dts": { "schema": { "local": [ "cara-20231218.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "cara-20231218_lab.xml" ] }, "presentationLink": { "local": [ "cara-20231218_pre.xml" ] }, "inline": { "local": [ "tm2333104d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://caratherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333104d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333104d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-126599-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-126599-xbrl.zip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